vTv Therapeutics (VTVT) EBIT Margin (2014 - 2026)

vTv Therapeutics has disclosed EBIT Margin across 11 years of filings, most recently posting 63.15% for Q1 2026.

• In Q1 2026, EBIT Margin changed N/A year-over-year to 63.15%; the TTM figure through Jun 2026 stood at 25.11% (up 15069254.0% YoY), while the FY2024 annual figure was 2377.58%, changed N/A from the prior year.
• EBIT Margin came in at 63.15% for Q1 2026 at vTv Therapeutics, up from 28776.47% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 63.15% in Q1 2026 to a low of 70477.78% in Q4 2022.
• Average EBIT Margin over 3 years is 24137.05%, with a median of 14669.59% recorded in 2024.
• The largest YoY upside for EBIT Margin was 5295556 bps in 2022 against a maximum downside of 10959 bps in 2022.
• Over 3 years, EBIT Margin stood at 70477.78% in 2022, then soared by 59 bps to 28776.47% in 2024, then soared by 100 bps to 63.15% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 63.15% in Q1 2026, 28776.47% in Q4 2024, and 562.7% in Q1 2024.